Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis

N. Gill¹, M. Pietrosanu², R. Gniadecki¹

¹*Division of Dermatology, Faculty of Medicine, ²Department of Mathematical & Statistical Sciences, Faculty of Science, University of Alberta, Edmonton, AB, Canada*

Correspondence: Robert Gniadecki, MD, Division of Dermatology, Faculty of Medicine, University of Alberta, 8-112 Clinical Science Building, 11350-83 Ave, Edmonton, AB, T6G 2G3, Canada, Tel: (780) 407-1555, Direct: (780) 407-1533, Fax: (780) 407-2996

Funding sources: None

Conflicts of interest: R.G. has received speaker's honoraria from Mallinckrodt, Janssen, AbbVie, Novartis and LEO Pharma; is on advisory boards for Mallinckrodt, Janssen, Amgen, AbbVie, Eli Lilly, Sanofi, Novartis and LEO Pharma; and is an investigator in clinical trials for Janssen, Celgene, AbbVie and LEO Pharma. N.G. and M.P. have no conflicts of interest to declare.

Keywords: Ixekizumab, Secukinumab, Crohn's disease, Ulcerative colitis, Number Needed to Harm, Absolute Risk, Hidradenitis suppurativa, Risk Stratification

Abstract

Background: Use of interleukin-17 inhibitors (IL-17i) in psoriasis has been associated with an increased risk of inflammatory bowel disease (IBD). However, the clinical significance of this association is not understood.

Objectives: To quantify the absolute risk of IBD in patients with psoriasis treated with IL-17i, stratified by known IBD risk factors.

Methods: Literature searches were performed to identify known IBD risk factors and the prevalences were quantified by a meta-analysis of proportions. The Bayesian model was used to estimate the probability of a new-onset or a flare of IBD in patients with psoriasis.

Results: The prevalence of Crohn's disease (CD) or ulcerative colitis (UC) in the general psoriasis population was 0.0010. Use of IL-17i increased the risk of CD to 0.0037 and UC to 0.0028, translating to a number needed to harm (NNH) of 373 for CD and 564 for UC. In patients who had concomitant hidradenitis suppurativa, the use of IL-17i was associated with a decrease in NNH for CD and UC to 18 and 76, respectively, whereas for patients with a family history of IBD, the NNH values were 6 (for CD) and 10 (for UC).

Conclusions: In patients with no risk factors, the probability of IBD flare or onset during IL-17i treatment is negligible and additional IBD screening procedures are not indicated. In contrast, the patients with psoriasis who have hidradenitis suppurativa or first-degree family history of IBD as risk factors should be monitored for signs and symptoms of CD and UC during IL-17i therapy.

Introduction

Psoriasis is a chronic immune-mediated inflammatory skin disorder affecting 2-3% of the Western population.¹ Interleukin-17A is a proinflammatory cytokine involved in the pathogenesis of psoriasis and is an effective therapeutic target.^{2,3} Secukinumab and ixekizumab are among the IL-17A inhibitors (IL-17i) currently approved in psoriasis and have shown superiority to placebo⁴ and other biologics⁵ with minimal adverse events. However, recent observations that IL-17i may exacerbate or even induce inflammatory bowel disease (IBD)⁶ led the Federal Drug Administration (FDA) to encourage caution when prescribing to patients with a history or risk of IBD.

IBD comprises Crohn's disease (CD), characterized by transmural inflammation in the gut, and ulcerative colitis (UC) in which inflammation is limited to the mucosal layer of the colon. Common clinical symptoms and signs include abdominal pain and diarrhoea, sometimes with hematochezia. The prevalence of CD and UC in North America ranges between 96.3 - 318.5 and 139.8 - 286.3 per 100,000 persons, respectively.⁷ Distinguishing CD from UC is important due to differences in management and prognosis. Surgical resection of the colon and rectum is considered curative in UC⁸ whereas CD has a 10-year postoperative recurrence rate of 44–55%.^{9,10} Ileocolonoscopy with ileal biopsies and imaging constitute the gold standard for diagnosis of IBD^{9,11} but an unequivocal classification may not be possible in up to 15% of cases.^{10,12} Endoscopy is not an efficient diagnostic technique in asymptomatic patients¹¹ and there are no robust, non-invasive screening methods to assess the risk of subclinical IBD in the population. Use of faecal calprotectin is a sensitive test measuring disease activity but should not be used for screening purposes as it would lead to a vast overestimation of the risk of IBD.¹³

Thus, the dermatologist prescribing IL-17i is faced with the practical challenge of carrying out a simple yet cost-effective assessment of the risk of IBD in psoriasis patients. The current FDA warning for secukinumab¹⁴ and ixekizumab¹⁴ does not provide any guidance on appropriate screening procedures in patients who do not have a diagnosis of IBD. There is, therefore, a need for a quantitative and clinically understandable estimate of the risk of IBD in a patient treated with IL-17i. To meet this clinical need we used the Bayesian approach to provide risk estimates of IBD in psoriasis patients treated with IL-17i.

Materials and Methods

Search Strategy

We searched the Ovid MEDLINE database for papers reporting risk factors for IBD. The inclusion criteria were: adult patients (age > 18 years), report of an IBD risk factor with a statistically significant association, and a reported risk factor that can objectively be assessed for in the clinic. For example, studies assessing components of diet as risk factors were not

considered as subjective and not readily reproducible. Subsequently, we performed separate searches for each individual risk factor to obtain the data on the prevalence of those risk factors. For the data in IL-17i treated patients, we pooled secukinumab and ixekizumab studies assuming that these drugs do not substantially differ in their ability to modulate IBD. Studies were considered for inclusion if they involved adult patients (age > 18), contained data required to calculate the prevalence of the given risk factor, reported original data and were written in English. Abstracts, unpublished data, and letters to the editor were also evaluated. Articles meeting the inclusion criteria after a title and abstract screen underwent full article review. The reference lists of all selected papers were further reviewed to identify additional potentially relevant articles.

The detailed search strategies are provided in supplementary **Appendix S1**. Results are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.¹⁵ This study is registered with PROSPERO.

Data extraction

A full-text review was performed on the included articles and the following data were collected: total number of controls (when available), number of controls affected with the IBD risk factor, the total number of IBD patients (UC, CD, or both), and number of IBD patients affected with the risk factor. In addition to these data points, we also collected the study author, date, design, and country.

Risk of Bias and Quality Assessment

Outliers were identified with externally standardized residuals in *R* version 3.6.1 (*R* Foundation for Statistical Computing). Absolute values of Z-scores greater than or equal to two were identified as outliers. Influential studies were identified as those with a Cook's distance larger than three times the mean value. Studies that were outliers and influential were assessed for quality with the Newcastle-Ottawa Scale (NOS). The tool includes three domains: selection, comparability, and outcome/exposure. The threshold for good quality was a minimum of 3 stars in the selection domain and 1 star in the comparability domain and 2 stars in the outcome/exposure domain. Influential outliers that were good quality according to the NOS were included in the study.

Model Development

The stepwise approach to the development of the computational model is shown in the supplementary **Table S1** and the final formula is given in **Equation 1**. A Bayesian approach was chosen over a frequentist approach due to its ability to use informed priors to generate a probability that accounts for known background information. We used a Bayesian framework to calculate the probability of development or flare-up of IBD given the presence of IBD risk factors which were considered as multiple priors in Bayes' formula. In the resulting **Equation 1** the risk factor prevalence was used as an equivalent of probability (*P*): *IBD*, Inflammatory Bowel Disease (either Crohn's disease or ulcerative colitis); *Pso*, Psoriasis; *HS*, Hidradenitis Suppurativa; *Smo*, Smoking status (current smoking for Crohn's disease and former smoking for ulcerative colitis); *FDR*, first degree relative with IBD; *IL17i*, Interleukin-17 inhibitor. In Bayesian convention, the symbol “−” indicates the absence of a given factor and the vertical bar between probabilities ($X|Y$) symbolizes the probability of *X* given *Y* is true.

$$P(IBM|Pso,HS,Smo,FDR,IL17i) = \frac{P(Pso|IBM) \cdot P(HS|IBM) \cdot P(Smo|IBM) \cdot P(FDR|IBM) \cdot P(IL17i|IBM) \cdot P(IBM)}{[P(Pso|IBM) \cdot P(HS|IBM) \cdot \dots \cdot P(IBM)] + [P(Pso|-IBM) \cdot P(HS|-IBM) \cdot \dots \cdot P(-IBM)]} \quad (1)$$

Two inputs were not available in the literature and thus required an expansion using Bayes' theorem: $P(IL-17i|IBM)$ and $P(FDR|-IBM)$. The proportion of individuals treated with IL-17i given the diagnosis of IBM, $P(IL-17i|IBM)$, can be calculated by inputting $P(IBM|IL17i)$, $P(IBM)$, and $P(IL17i)$ as shown in supplementary **Equation S1**. $P(IL17i)$, i.e. the probability of receiving IL-17i, is per definition 100% as all patients in our theoretical scenario will be receiving IL-17i. The other two inputs, $P(IBM)$ and $P(IBM|IL17i)$, the prevalence of IBM among patients on an IL-17i, are reported in the literature. The second expanded input is $P(FDR|-IBM)$, as the prevalence of having a first-degree relative with IBM among people without a current diagnosis of IBM is not reported. The expansion of $P(FDR|-IBM)$ is shown in supplementary **Equation S2**. $P(FDR)$, the probability of having a first degree relative with IBM in the general population, is a required input in the expansion of $P(FDR|-IBM)$. As $P(FDR)$ is not reported in the literature, it was estimated using the prevalence of IBM,⁷ Canadian population of 37,058,856,¹⁶ and the Canadian fertility rate of 1.66¹⁷ as shown in supplementary **Equation S3**. This estimation was made assuming the child is the proband and that each family has a maximum of one affected FDR.

We considered the following scenarios when estimating the impact of IL17i on IBM risk: i) the baseline scenario compared psoriasis patient's probability of IBM development (**Table S1**, Step 1a) with that of a psoriasis patient on IL-17i (**Table S1**, Step 1b), ii) the probability of IBM in a psoriasis patient with HS (**Table S1**, Step 2a) to a psoriasis patient with HS and on IL-17i (**Table S1**, Step 2b), iii) the probability of IBM in a psoriasis patient with a positive FDR (**Table S1**, Step 3a) to a psoriasis patient with a positive FDR and on IL-17i (**Table S1**, Step 3b), and iv) the probability of IBM in a psoriasis patient with a positive smoking status (**Table S1**, Step 4a) to a psoriasis patient with a positive smoking status on IL-17i (**Table S1**, Step 4b).

Statistical analysis

Metaanalyses of the prevalence of risk factors were performed using *R* version 3.6.1. Proportions were first transformed using the double-arcsine method. These transformed proportions then underwent an inverse-variance weighted random-effects metaanalysis using the DerSimonian and Laird method.¹⁸ The double-arcsine transformation was chosen over logit transformation as it is better able to stabilize variances for proportions closer to 0 or 1. Logit transformations overestimate variances for proportions close to 0 or 1 resulting in a small study with a prevalence around 0.5 outweighing a larger study with a smaller prevalence.¹⁹ We obtained pooled prevalences with 95% confidence intervals (CIs) of each IBM risk factor in CD and UC separately (**Table S7**). Heterogeneity was assessed using I^2 , which describes the total variance between studies due to heterogeneity of included studies.²⁰

Results

Study selection

The literature search returned 29 studies that identified risk factors for IBD (supplementary **Fig. S2**). The following risk factors were identified: hidradenitis suppurativa (HS), psoriasis (Pso), first-degree relative with IBD (FDR), and smoking status (Smo, current smoking in CD and former smoking in UC).

IBD and Psoriasis

We found 814 potentially relevant studies of which 7 studies^{21–27} were included in the meta-analysis (supplementary **Fig. S3**): one case-control, two cohort, and four cross-sectional studies. These studies included 28,883 total CD patients and 62,580 total UC patients (**Table S2**). A metaanalysis returned a pooled prevalence of psoriasis of 0.021 (95% CI: 0.015 – 0.029) and 0.014 (95% CI: 0.011 - 0.018) in CD and UC, respectively (**Table S7**). Using a general prevalence of CD of 0.096%⁷ and psoriasis of 2.0%¹ combined with the pooled prevalence of psoriasis in CD (**Table S1**, Step 1a), the probability of CD or UC development given the presence of psoriasis ($P(\text{CD}|\text{Psoriasis})$ and $P(\text{UC}|\text{Psoriasis})$) was in both instances 0.0010.

IL-17i increase the risk of IBD in psoriasis patients

The MEDLINE search returned 369 studies from which 9 reports^{28–34} were included in the metaanalysis (supplementary **Fig. S4**). These nine studies referred to results from 29 clinical trials comprising 8,800 patients on an IL-17i (2,809 on ixekizumab, and 5,991 on secukinumab) for psoriasis, psoriatic arthritis, or ankylosing spondylitis (supplementary **Table S3**). Adverse events for these clinical trials were obtained from the US National Library of Medicine Clinical Trials Results Database. For two trials, FUTURE 2 and MEASURE 2, study data was not publicly available on the database and results were instead obtained from McInnes et al. 2015³⁵ and Baeten et al. 2015³⁶, respectively. The metaanalysis returned a pooled prevalence of IBD onset or flare in patients on IL-17i of 0.0019 (95% CI: 0.0013 – 0.0027) and 0.0022 (95% CI: 0.0015 - 0.0029) for CD and UC respectively (**Table S7**). Building on the previously calculated probability of CD and UC in psoriasis, the addition of IL-17 inhibition as a risk factor (**Table S1**, Step 1b) increased the probability of CD development from 0.0010 to 0.0037 and increased the probability of UC from 0.0010 to 0.0028 (**Table 1** and **Table 2**).

Impact of risk factors on IBD in patients exposed to IL-17i

The literature search identified 3 risk factors associated with IBD: concomitant hidradenitis suppurativa (HS)^{37–41} (supplementary **Fig. S5** and **Table S4**), presence of the first-degree relative with IBD^{42–57} (supplementary **Fig. S6** and **Table S5**) and smoking^{58–88} (supplementary **Fig. S7**, **Table S6**). Metaanalyses produced values of pooled prevalences for each risk factor in CD and UC that were included in the Bayesian model (supplementary **Table S7**).

Bayesian modelling was done for both CD and UC to calculate the average, lower, and upper estimate of the probability of IBD development given risk factors using the average, lower, and upper bound estimates from the 95% confidence intervals for each risk factor, respectively (**Table 1** and **Table 2**). Finally, **Table 3** gives the values of the absolute risk increase of IBD

attributed to the use of IL-17i. They allowed for calculating the number needed to harm (NNH) that reflects the number of psoriasis patients with a given risk factor profile who, if treated with IL-17i, would generate one case of CD or UC attributed to the use of the biologic.

Study heterogeneity

The metaanalyses of proportions for both CD and UC in IL-17i showed low heterogeneities ($I^2=0\%$) and statistically insignificant p-values of ($p<0.800$) and ($p<0.915$) respectively. The remaining metaanalyses of psoriasis, smoking status, FDR, and HS in IBD showed high heterogeneities with I^2 values greater than 75% and statistically significant p-values <0.001 (supplementary **Table S7**).

Discussion

To our knowledge, this is the first study using Bayesian inference to quantify the probability of IBD flare or onset with IL-17i therapy. We confirmed that psoriasis is associated with both CD and UC. The association with CD seems to be stronger⁸⁹ and our data showed that the prevalence of psoriasis in CD was 1.5 times greater than the prevalence of psoriasis in UC. Hitherto, the IBD risk in psoriasis has been done in terms of the relative change (relative risks, odds ratios or exposure-adjusted incidence rates) which is not intuitively understandable to the clinician. This created much debate on whether psoriasis patients should be screened for IBD before initiation of IL-17i therapy and what are the correct screening procedures. We have therefore focused on absolute risk which is recognized as a relevant, valid, and clinically useful measure included in the POEMs outcomes (Patient-Oriented Evidence that Matters).^{90,91} Especially, the use of the number needed to treat and the number needed to harm (NNH) as POEMs outcomes have been advocated and therefore adopted in our current study.

Our data clearly show that screening of asymptomatic psoriasis patients for IBD before initiation of IL-17i is not an efficient approach if the patient does not have any IBD risk factors. In those patients, the NNH necessary to see one case of IBD attributable to IL-17i is 373 (for CD) and 556 (for UC). The number needed to treat (NNT) to achieve PASI75 (1.18 for ixekizumab and 1.29 for secukinumab⁹²) allow calculating the values of likelihood to be helped or harmed (LHH = NNH/NNT) to provide further perspective to the clinical value of IL17i. LLH values for IL17i indicate that the patient is $\cong 300$ times more likely to benefit from the treatment than to be harmed.

However, clinical decision making should be modified for patients with preexisting IBD risk factors. Our metaanalysis uncovered three potential risk factors: smoking, family history (FDR), and co-morbid HS, of which only the two latter risk factors significantly affected NNH values. HS was very strongly associated with CD (58-fold increase in the probability of CD compared to a 25-fold increase of UC in psoriasis patients) and use of IL-17i in psoriasis patients with HS vastly increased the risk of IBD (NNH of 18 and 76 for CD and UC, respectively). Patients with HS have thus a $\cong 20$ -fold reduced LHH as compared with patients without IBD risk factors which could be used as an argument to avoid IL17i in those patients as the first-line antipsoriatic agent.

There is strong evidence suggesting a genetic basis for IBD. The polygenic nature of CD and UC was established with a genome search identifying susceptibility loci on chromosomes 12, 7, and

3.⁹³ First degree relatives of IBD patients have a 10-15-fold higher risk of developing IBD.^{57,93} Positive family history has been reported as the strongest recognizable risk factor for IBD,⁹⁴ and was found to be the strongest risk factor in our study resulting in IL17i-related NNH of only 6 (for CD) and 10 (for UC).

This study is subject to limitations. Most importantly, we assumed independence between risk factors, which may not necessarily be the case for all risk factors, e.g. genetic predisposition to IBD and HS. Second, a significant proportion of the studies included were cross-sectional studies largely relying on the participants' self-reporting of risk factors which may lead to recall bias. Third, there may be other risk factors yet to be discovered that would further improve our model.

In summary, the results of our study propose a simple approach to identify patients at increased risk for IBD in the context of IL-17i treatment. Asymptomatic patients who do not have any family history of IBD and do not have a comorbid HS can safely be treated with IL-17i as their added risk of inflammatory bowel disease is negligible and by far outweighed by the therapeutic benefit. In contrast, those who have one or both of those mentioned risk factors should be treated with caution and monitored for a new-onset IBD.

References

- 1 Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. *Ann Rheum Dis* 2005; **64 Suppl 2**:ii18–23; discussion ii24–5.
- 2 Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. *Clin Rev Allergy Immunol* 2018; **55**:379–90.
- 3 Ringham L, Prusinkiewicz P, Gniadecki R. Skin Patterning in Psoriasis by Spatial Interactions between Pathogenic Cytokines. *iScience* 2019; **20**:546–53.
- 4 Lynde CW, Beecker J, Dutz J, *et al.* Treating to Target(s) With Interleukin-17 Inhibitors. *J Cutan Med Surg* 2019; **23**:3S – 34S.
- 5 Puig L, Notario J, Jiménez-Morales A, *et al.* Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. *J Dermatolog Treat* 2017; **28**:623–30.
- 6 Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. *J Dermatolog Treat* 2018; **29**:13–8.
- 7 Ng SC, Shi HY, Hamidi N, *et al.* Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2018; **390**:2769–78.
- 8 Bohl JL, Sobba K. Indications and Options for Surgery in Ulcerative Colitis. *Surg Clin North Am* 2015; **95**:1211–32, vi.
- 9 Baumgart DC, Sandborn WJ. Crohn's disease. *Lancet* 2012; **380**:1590–605.
- 10 Melmed GY, Elashoff R, Chen GC, *et al.* Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. *Clin Gastroenterol Hepatol* 2007; **5**:602–8; quiz 525.
- 11 Lamb CA, Kennedy NA, Raine T, *et al.* British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019. doi:10.1136/gutjnl-2019-318484.

- 12 Guindi M, Riddell RH. Indeterminate colitis. *J Clin Pathol* 2004; **57**:1233–44.
- 13 Ayling RM, Kok K. Fecal Calprotectin. *Adv Clin Chem* 2018; **87**:161–90.
- 14 U.S. Food and Drug Administration. Cosentyx - Prescribing Information Sheet [WWW Document]. URL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125504s000lbl.pdf [accessed on 11 November 2019].
- 15 Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009; **62**:1006–12.
- 16 Population estimates on July 1st, by age and sex [WWW Document]. Statistics Canada. URL <https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501> [accessed on 4 September 2019].
- 17 International perspective [WWW Document]. Statistics Canada. 2018. URL <https://www150.statcan.gc.ca/n1/pub/11-402-x/2011000/chap/pop/pop03-eng.htm> [accessed on 4 September 2019].
- 18 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**:177–88.
- 19 Barendregt JJ, Doi SA, Lee YY, *et al.* Meta-analysis of prevalence. *J Epidemiol Community Health* 2013; **67**:974–8.
- 20 Ryan R. Ryan 2016.pdf. 2016. URL <http://cccr.org.cochrane.org> [accessed on 7 September 2019].
- 21 Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. *Gastroenterology* 2005; **129**:827–36.
- 22 Egeberg A, Mallbris L, Warren RB, *et al.* Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. *Br J Dermatol* 2016; **175**:487–92.
- 23 Kim M, Choi KH, Hwang SW, *et al.* Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. *J Am Acad Dermatol* 2017; **76**:40–8.
- 24 Persson PG, Leijonmarck CE, Bernell O, *et al.* Risk indicators for inflammatory bowel disease. *Int J Epidemiol* 1993; **22**:268–72.
- 25 Sategna-Guidetti C., Bracco E., Marucco E., Bianco L. Psoriasis and Crohn's Disease in Italy. *Dig Dis Sci* 1988; **33**:1496.
- 26 Vavricka SR, Brun L, Ballabeni P, *et al.* Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol* 2011; **106**:110–9.
- 27 Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. *British Journal of Dermatology* 1982; **106**:323–30.
- 28 van der Heijde D, Cheng-Chung Wei J, Dougados M, *et al.* Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. *Lancet* 2018; **392**:2441–51.
- 29 Marzo-Ortega H, Sieper J, Kivitz A, *et al.* Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. *Arthritis Care Res* 2017; **69**:1020–9.
- 30 Gordon KB, Blauvelt A, Papp KA, *et al.* Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque

- Psoriasis. *N Engl J Med* 2016; **375**:345–56.
- 31 Targan SR, Feagan B, Vermeire S, *et al.* A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease. *Am J Gastroenterol* 2016; **111**:1599–607.
 - 32 van de Kerkhof PCM, Griffiths CEM, Reich K, *et al.* Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. *J Am Acad Dermatol* 2016; **75**:83–98.e4.
 - 33 Reich K, Leonardi C, Langley RG, *et al.* Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. *J Am Acad Dermatol* 2017; **76**:441–8.e2.
 - 34 Schreiber S, Colombel J-F, Feagan BG, *et al.* Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. *Ann Rheum Dis* 2019; **78**:473–9.
 - 35 McInnes IB, Mease PJ, Kirkham B, *et al.* Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2015; **386**:1137–46.
 - 36 Baeten D, Sieper J, Braun J, *et al.* Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *N Engl J Med* 2015; **373**:2534–48.
 - 37 Aletaha D, Epstein AJ, Skup M, *et al.* Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study. *Adv Ther* 2019; **36**:1672–83.
 - 38 Ramos-Rodriguez AJ, Timmerman D, Khan A, *et al.* The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014. *Int J Dermatol* 2018; **57**:547–52.
 - 39 van der Zee HH, de Winter K, van der Woude CJ, Prens EP. The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. *Br J Dermatol* 2014; **171**:673–5.
 - 40 van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. *Br J Dermatol* 2010; **162**:195–7.
 - 41 Yadav S, Singh S, Edakkanambeth Varayil J, *et al.* Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. *Clin Gastroenterol Hepatol* 2016; **14**:65–70.
 - 42 Bayless TM, Tokayer AZ, Polito JM 2nd, *et al.* Crohn’s disease: concordance for site and clinical type in affected family members--potential hereditary influences. *Gastroenterology* 1996; **111**:573–9.
 - 43 Carbonnel F, Macaigne G, Beaugerie L, *et al.* Crohn’s disease severity in familial and sporadic cases. *Gut* 1999; **44**:91–5.
 - 44 Cipolla C, Magliocco A, Oliva L, Cottone M. Familial aggregation of inflammatory bowel disease in a Mediterranean area. *Eur J Epidemiol* 1996; **12**:205–10.
 - 45 Freeman HJ. Familial Crohn’s Disease in Single or Multiple First-Degree Relatives. *J Clin Gastroenterol* 2002; **35**:9–13.
 - 46 Fujii T, Sato M, Hosoi K, *et al.* Assessment of the Family History of Patients With Ulcerative Colitis at a Single Center in Japan. *J Pediatr Gastroenterol Nutr* 2016; **63**:512–5.

- 47 Halme L, Turunen U, Heliö T, *et al.* Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. *Scand J Gastroenterol* 2002; **37**:692–8.
- 48 Probert CS, Jayanthi V, Hughes AO, *et al.* Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. *Gut* 1993; **34**:1547–51.
- 49 Mayberry JF, Rhodes J, Newcombe RG. Familial prevalence of inflammatory bowel disease in relatives of patients with Crohn's disease. *Br Med J* 1980; **280**:84.
- 50 Monsén U, Bernell O, Johansson C, Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease. *Scand J Gastroenterol* 1991; **26**:302–6.
- 51 Park JB, Yang S-K, Byeon J-S, *et al.* Familial occurrence of inflammatory bowel disease in Korea. *Inflamm Bowel Dis* 2006; **12**:1146–51.
- 52 Peeters M, Nevens H, Baert F, *et al.* Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. *Gastroenterology* 1996; **111**:597–603.
- 53 Roma ES, Panayiotou J, Pachoula J, *et al.* Inflammatory bowel disease in children: the role of a positive family history. *Eur J Gastroenterol Hepatol* 2010; **22**:710–5.
- 54 Schiff ER, Frampton M, Semplici F, *et al.* A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population. *Dig Dis Sci* 2018; **63**:3049–57.
- 55 Yang H, McElree C, Roth MP, *et al.* Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. *Gut* 1993; **34**:517–24.
- 56 Zlotogora J, Zimmerman J, Rachmilewitz D. Prevalence of inflammatory bowel disease in family members of Jewish Crohn's disease patients in Israel. *Dig Dis Sci* 1991; **36**:471–5.
- 57 Orholm M, Munkholm P, Langholz E, *et al.* Familial occurrence of inflammatory bowel disease. *N Engl J Med* 1991; **324**:84–8.
- 58 Abraham N, Selby W, Lazarus R, Solomon M. Is smoking an indirect risk factor for the development of ulcerative colitis? An age- and sex-matched case-control study. *JGHJournal of Gastroenterology and Hepatology* 2003; **0815**:931.
- 59 Benoni C, Nilsson A. Smoking habits in patients with inflammatory bowel disease. A case-control study. *Scand J Gastroenterol* 1987; **22**:1130–6.
- 60 Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. *Am J Gastroenterol* 2006; **101**:993–1002.
- 61 Corrao G, Tragnone A, Caprilli R, *et al.* Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. *Int J Epidemiol* 1998; **27**:397–404.
- 62 Cosnes J, Carbonnel F, Beaugerie L, *et al.* Effects of cigarette smoking on the long-term course of Crohn's disease. *Gastroenterology* 1996; **110**:424–31.
- 63 De Bie C, Ballet V, Hendriks N, *et al.* Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2015; **42**:1294–302.
- 64 De Saussure P, Clerson P, Prost P-L, *et al.* Appendectomy, smoking habits and the risk of developing ulcerative colitis: a case control study in private practice setting. *Gastroentérologie Clinique et Biologique* 2007; **31**:493–7.

- 65 Franceschi S, Panza E, La Vecchia C, *et al.* Nonspecific inflammatory bowel disease and smoking. *Am J Epidemiol* 1987; **125**:445–52.
- 66 García Rodríguez LA, González-Pérez A, Johansson S, Wallander M-A. Risk factors for inflammatory bowel disease in the general population. *Aliment Pharmacol Ther* 2005; **22**:309–15.
- 67 Gheorghe C, Pascu O, Gheorghe L, *et al.* Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. *Eur J Gastroenterol Hepatol* 2004; **16**:1153–9.
- 68 Han DY, Fraser AG, Dryland P, Ferguson LR. Environmental factors in the development of chronic inflammation: A case–control study on risk factors for Crohn’s disease within New Zealand. *Mutat Res/Fundam Mol Mech Mutag* 2010; **690**:116–22.
- 69 Hansen TS, Jess T, Vind I, *et al.* Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. *J Crohns Colitis* 2011; **5**:577–84.
- 70 Jiang L, Xia B, Li J, *et al.* Risk Factors for Ulcerative Colitis in a Chinese Population. *Journal of Clinical Gastroenterology*. 2007; **41**:280–4.
- 71 Katschinski B, Logan RF, Edmond M, Langman MJ. Smoking and sugar intake are separate but interactive risk factors in Crohn’s disease. *Gut* 1988; **29**:1202–6.
- 72 Lakatos PL, Vegh Z, Lovasz BD, *et al.* Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. *Inflamm Bowel Dis* 2013; **19**:1010–7.
- 73 Lindberg E, Tysk C, Andersson K, Järnerot G. Smoking and inflammatory bowel disease. A case control study. *Gut* 1988; **29**:352–7.
- 74 Nakamura Y, Labarthe DR. A case-control study of ulcerative colitis with relation to smoking habits and alcohol consumption in Japan. *Am J Epidemiol* 1994; **140**:902–11.
- 75 Niewiadomski O, Studd C, Wilson J, *et al.* Influence of food and lifestyle on the risk of developing inflammatory bowel disease. *Intern Med J* 2016; **46**:669–76.
- 76 Odes HS, Fich A, Reif S, *et al.* Effects of current cigarette smoking on clinical course of Crohn’s disease and ulcerative colitis. *Dig Dis Sci* 2001; **46**:1717–21.
- 77 Persson PG, Ahlbom A, Hellers G. Inflammatory bowel disease and tobacco smoke--a case-control study. *Gut* 1990; **31**:1377–81.
- 78 Reif S, Klein I, Arber N, Gilat T. Lack of association between smoking and inflammatory bowel disease in Jewish patients in Israel. *Gastroenterology* 1995; **108**:1683–7.
- 79 Reif S, Lavy A, Keter D, *et al.* Lack of association between smoking and Crohn’s disease but the usual association with ulcerative colitis in Jewish patients in Israel: a multicenter study. *Am J Gastroenterol* 2000; **95**:474–8.
- 80 Russel MGVM, Volovics A, Schoon EJ, *et al.* Inflammatory Bowel Disease: Is There Any Relation Between Smoking Status and Disease Presentation? *Inflamm Bowel Dis* 1998; **4**:182–6.
- 81 Salgado VCL, Luiz RR, Boechat N, *et al.* Crohn’s disease environmental factors in the developing world: A case-control study in a statewide catchment area in Brazil. *World J Gastroenterol* 2017; **23**:5549–56.
- 82 Salih A, Widbom L, Hultdin J, Karling P. Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study. *Scand J*

- Gastroenterol* 2018; **53**:173–8.
- 83 Somerville KW, Logan RF, Edmond M, Langman MJ. Smoking and Crohn's disease. *Br Med J* 1984; **289**:954–6.
 - 84 Vcev A, Pezerovic D, Jovanovic Z, *et al.* A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010. *Wien Klin Wochenschr* 2015; **127**:345–54.
 - 85 Vegh Z, Burisch J, Pedersen N, *et al.* Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. *J Crohns Colitis* 2014; **8**:1506–15.
 - 86 Wang P, Hu J, Ghadermarzi S, *et al.* Smoking and Inflammatory Bowel Disease: A Comparison of China, India, and the USA. *Dig Dis Sci* 2018; **63**:2703–13.
 - 87 Boyko EJ, Koepsell TD, Perera DR, Inui TS. Risk of ulcerative colitis among former and current cigarette smokers. *N Engl J Med* 1987; **316**:707–10.
 - 88 Breuer-Katschinski BD, Holländer N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. *Eur J Gastroenterol Hepatol* 1996; **8**:225–8.
 - 89 Cohen AD, Dreiherr J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. *J Eur Acad Dermatol Venereol* 2009; **23**:561–5.
 - 90 Duncan B, Ables AZ. Do drug treatment POEMs report data in clinically useful ways? *J Fam Pract* 2013; **62**:E1–5.
 - 91 Grad R, Pluye P, Tang D, *et al.* Patient-oriented evidence that matters (POEMs)TM suggest potential clinical topics for the Choosing WiselyTM campaign. *J Am Board Fam Med* 2015; **28**:184–9.
 - 92 Armstrong AW, Betts KA, Signorovitch JE, *et al.* Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. *Curr Med Res Opin* 2018; **34**:1325–33.
 - 93 Peña AS, Crusius JB. Genetics of inflammatory bowel disease: implications for the future. *World J Surg* 1998; **22**:390–3.
 - 94 Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. *Ann Gastroenterol Hepatol* 2018; **31**:14–23.

Table 1. Probability of Crohn's disease (CD) in psoriasis patients stratified by IBD risk factors.¹

Risk Factor (RF)	Control ²			Patient on IL-17i ²		
	<i>P (CD Psoriasis, RF)</i> (%)	Lower bound (%)	Upper bound (%)	<i>P (CD Psoriasis, IL-17i, RF)</i> (%)	Lower bound (%)	Upper bound (%)
No RF	0.10	0.07	0.14	0.37	0.18	0.69
FDR	36.14	18.99	53.39	53.56	24.89	76.08
Current smoking	0.27	0.16	0.43	0.55	0.22	1.18
HS	5.93	2.69	10.98	11.38	3.76	25.52

¹Abbreviations: CD, Crohn's disease; FDR, first degree relative with inflammatory bowel disease; HS, hidradenitis suppurativa; IL-17i, interleukin-17 inhibitor; RF, risk factor

²Upper and lower bounds calculated with lower and upper estimates of the prevalence of risk factors, respectively.

Table 2. Probability of ulcerative colitis (UC) in psoriasis patients stratified by IBD risk factors.¹

Risk Factor (RF)	Control ²			Patient on IL-17i ²		
	<i>P (UC Psoriasis, RF)</i> (%)	Lower bound (%)	Upper bound (%)	<i>P (UC Psoriasis, IL-17i, RF)</i> (%)	Lower bound (%)	Upper bound (%)
No RF	0.10	0.08	0.12	0.28	0.15	0.46
FDR	29.67	13.85	46.65	39.60	15.03	64.58
Former smoking	0.35	0.23	0.49	0.54	0.26	1.02
HS	2.47	1.00	4.83	3.78	1.10	9.57

¹Abbreviations: UC, ulcerative colitis; FDR, first degree relative with inflammatory bowel disease; HS, hidradenitis suppurativa; IL-17i, interleukin-17 inhibitor; RF, risk factor

²Upper and lower bounds calculated with lower and upper estimates of the prevalence of risk factors, respectively.

Table 3. Increase in the absolute risk of Crohn’s disease (CD) or ulcerative colitis (UC) in a patient with different IBD risk factors exposed to IL-17i¹

Risk factor <i>P</i> (IBD <i>RF</i>)	CD		UC	
	AR Increase	NNH	AR Increase	NNH
<i>P</i> (IBD <i>Psoriasis</i>)	0.27%	373	0.18%	564
<i>P</i> (IBD <i>Psoriasis, Smoking</i> ²)	0.28%	357	0.19%	523
<i>P</i> (IBD <i>Psoriasis, HS</i>)	5.46%	18	1.31%	76
<i>P</i> (IBD <i>Psoriasis, FDR</i>)	17.43%	6	9.92%	10

¹Abbreviations: AR, absolute risk; CD, Crohn’s disease; FDR, first-degree relative with IBD; HS, hidradenitis suppurativa, IBD, inflammatory bowel disease; NNH, number needed to harm attributed to IL-17i; UC, ulcerative colitis.

²Smoking: current smoking for CD and former smoking for UC.